Clinical Trial Update: Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) [Phase 2]

View source ↗

Summary

A Phase 2 study of oral panobinostat (LBH589) in relapsed or refractory chronic lymphocytic leukemia and mantle cell lymphoma has been terminated, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Farydak (panobinostat)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2012-03-28